» Articles » PMID: 37560797

Nonalcoholic Fatty Liver Disease As a Systemic Disease and the Need for Multidisciplinary Care

Overview
Journal Gut Liver
Specialty Gastroenterology
Date 2023 Aug 10
PMID 37560797
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, and there has been a rapid increase in cases worldwide. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma and is also associated with an increased risk of cardiovascular disease or exacerbation of other organ diseases, thus posing a significant health problem from both a medical and a socioeconomic perspective. NAFLD is a systemic disease and requires the involvement of numerous medical professionals. Multidisciplinary collaboration, in which different professionals within different specialties come together and work together toward a common goal, supports better patient care by integrating perspectives of multiple experts and facilitating the exchange of opinions. Due to the large number of potential patients, gastroenterologists and hepatologists cannot manage the patients alone, and collaboration between specialists in various fields, including family doctors, dentists, nutritionists, and pharmacists is required for treatment of NAFLD. This review will discuss NAFLD from the perspective of various specialties and introduce multidisciplinary collaboration.

Citing Articles

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.

Takawy M, Abdelmalek M Curr Diab Rep. 2025; 25(1):23.

PMID: 39964660 DOI: 10.1007/s11892-025-01579-1.


The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.

Khaliq A, Badshah H, Shah Y, Rehman I, Khan K, Ming L Medicine (Baltimore). 2024; 103(45):e40356.

PMID: 39533572 PMC: 11556963. DOI: 10.1097/MD.0000000000040356.


Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis.

Maurelli M, Gisondi P, Bellinato F, Mantovani A, Targher G, Girolomoni G J Clin Med. 2023; 12(18).

PMID: 37762996 PMC: 10531586. DOI: 10.3390/jcm12186057.

References
1.
Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T . Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021; 56(11):1022-1032. PMC: 8531127. DOI: 10.1007/s00535-021-01828-6. View

2.
Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R . Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67(6):1265-1273. DOI: 10.1016/j.jhep.2017.07.027. View

3.
Kim D, Yoo E, Li A, Tighe S, Cholankeril G, Harrison S . Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019; 50(5):590-598. DOI: 10.1111/apt.15395. View

4.
Alakhali M, Al-Maweri S, Al-Shamiri H, Al-Haddad K, Halboub E . The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review. Clin Oral Investig. 2018; 22(9):2965-2974. DOI: 10.1007/s00784-018-2726-1. View

5.
. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View